[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alto Neuroscience Inc (ANRO)

Alto Neuroscience Inc (ANRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 768,940
  • Shares Outstanding, K 31,946
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,240 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.03

Options Overview Details

View History
  • Implied Volatility 99.75% (+5.72%)
  • Historical Volatility 74.78%
  • IV Percentile 8%
  • IV Rank 3.16%
  • IV High 756.33% on 05/16/25
  • IV Low 78.34% on 04/21/26
  • Expected Move (DTE 7) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 1,294
  • Open Int (30-Day) 2,565
  • Expected Range 24.72 to 24.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.56
  • Number of Estimates 6
  • High Estimate $-0.48
  • Low Estimate $-0.63
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) -5.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.82 +18.06%
on 04/09/26
28.44 -13.58%
on 04/22/26
+2.87 (+13.22%)
since 04/08/26
3-Month
14.80 +66.08%
on 02/09/26
28.44 -13.58%
on 04/22/26
+9.36 (+61.50%)
since 02/06/26
52-Week
2.15 +1,043.26%
on 06/30/25
28.44 -13.58%
on 04/22/26
+22.39 (+1,022.37%)
since 05/08/25

Most Recent Stories

More News
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7...

ANRO : 24.43 (+1.50%)
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial...

ANRO : 24.43 (+1.50%)
Stocks Recover on Hopes Strait of Hormuz Could Soon Reopen

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.11%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.11%. June E-mini...

ALK : 40.76 (+0.42%)
APO : 130.21 (+1.89%)
UAL : 100.26 (+0.56%)
ARES : 126.44 (+2.67%)
CARR : 68.28 (+1.58%)
$IUXX : 29,052.07 (+1.71%)
ZNM26 : 110-240 (+0.21%)
MTDR : 55.68 (+0.89%)
TSLA : 428.82 (+4.14%)
ESM26 : 7,415.25 (+0.71%)
NCLH : 17.25 (+0.17%)
BX : 123.70 (+1.12%)
Stocks Pare Losses on Hormuz Report

The S&P 500 Index ($SPX ) (SPY ) today is down -0.06%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.20%. June E-mini S&P futures...

ALK : 40.76 (+0.42%)
AMAT : 433.18 (+5.49%)
UAL : 100.26 (+0.56%)
MPC : 246.80 (+1.87%)
CVX : 181.65 (-0.47%)
$IUXX : 29,052.07 (+1.71%)
ASML : 1,555.50 (+2.56%)
ZNM26 : 110-240 (+0.21%)
OXY : 53.77 (-0.32%)
MTDR : 55.68 (+0.89%)
TSLA : 428.82 (+4.14%)
ESM26 : 7,415.25 (+0.71%)
Stocks Sink as President Trump Signals Iran War Will Drag On

The S&P 500 Index ($SPX ) (SPY ) today is down -1.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. June E-mini S&P futures...

ALK : 40.76 (+0.42%)
APO : 130.21 (+1.89%)
GOOGL : 399.03 (+0.26%)
ARES : 126.44 (+2.67%)
AAPL : 292.66 (+1.82%)
SNDK : 1,491.76 (+11.33%)
HL : 18.47 (+2.21%)
CDE : 18.51 (+2.15%)
OXY : 53.77 (-0.32%)
TSLA : 428.82 (+4.14%)
FANG : 188.85 (-0.84%)
STX : 790.80 (+3.18%)
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052)...

ANRO : 24.43 (+1.50%)
Alto Neuroscience Announces $120 Million Private Placement Financing

– Financing led by Commodore Capital with participation from new and existing biotech focused investors – –  Alto expects to use the proceeds of the financing to...

ANRO : 24.43 (+1.50%)
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – ...

ANRO : 24.43 (+1.50%)
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 24.43 (+1.50%)
Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 24.43 (+1.50%)

Business Summary

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

See More

Key Turning Points

3rd Resistance Point 25.71
2nd Resistance Point 25.08
1st Resistance Point 24.58
Last Price 24.43
1st Support Level 23.45
2nd Support Level 22.82
3rd Support Level 22.32

See More

52-Week High 28.44
Last Price 24.43
Fibonacci 61.8% 18.40
Fibonacci 50% 15.30
Fibonacci 38.2% 12.19
52-Week Low 2.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.